We have produced transgenic mice using the mouse placental lactogen type II promoter to force and restrict the expression of the mouse major histocompatibility complex ( 
INTRODUCTION
The paradox, first described by P. Medawar [1] , of the survival and development of the fetus in its mother's genetically different body remains to be fully elucidated. The precise cellular and molecular mechanisms involved in the phenomenon are still largely unknown. Recent hypotheses favor the role of fetal-maternal interactions establishing a state of maternal nonaggression, although fetal antigens are recognized by the mother. Local phenomena at the placental level have been uncovered and range from the local production of potent immunoregulatory factors [2] [3] [4] [5] [6] , immune response shifts from inflammatory/cytotoxic Th1 cells to Th2-type cells [7] [8] [9] [10] , to the negative regulation of expres- 1 This work has been supported in part by INSERM, the Association pour la Recherche contre le Cancer (ARC) and the Fondation pour la Recherche Médicale. D.A.-A. received a fellowship from the Fondation pour la Recherche Médicale and A.L. was supported by the European Community.
sion of major histocompatibility complex (MHC) genes [11] [12] [13] [14] , the establishment of an immune privilege [15] [16] [17] , and more recently, the upregulation of tryptophan catabolism [18] and the inhibition of complement activation [19] . Systemic events in the mother's organism include the hormonal down-regulation of T [20] and B lymphopoiesis [21, 22] in thymus and bone marrow, respectively. More recently, the modulation of fetus-specific T-or B-cell reactivity in maternal lymphoid organs has been described in T cell receptor (TcR) [23, 24] or B cell receptor (BcR)-transgenic (Tg) [25] mouse models. Thus, accumulating evidence in the literature suggests that the success of mammalian viviparity relies on the dual capacity of the fetus to escape a potentially damaging maternal immune reaction as well as to induce a state of functional tolerance in the mother's body.
While the maternal immune system must not react aggressively against the fetus as a foreign tissue, it must remain competent for defense against microbial infections. We have addressed the important question of the regulation of expression of polymorphic MHC gene products within the placenta. The MHC class Ia and II genes are defined as polymorphic because of the great number of alleles at each locus and their high frequency in a given species. The MHC class I molecules are present on the vast majority of adult tissues, and they bind peptides derived from intracellular degradation of viral, bacterial, or endogenous proteins [26] . They present these endogenous peptides on the cell surface to CD8 ϩ T cells. The MHC class II molecules are present on monocytic/macrophage cells, dendritic cells, and B lymphocytes and bind mostly peptides derived from proteins coming from the endocytic pathway [27] . They present them to CD4 ϩ T cells. Hence, the main function of MHC molecules is to participate in immune responses against pathogens. They also are the targets of allogeneic graft rejection, as host T cells react against allogeneic donor MHC molecules that they recognize either directly or through the presentation of allogeneic peptides by the host self-MHC molecules [28] . MHC nonclassical or class Ib molecules are less polymorphic, expressed at lower levels, and have a more restricted tissue distribution than class Ia molecules. Their high degree of homology has led to uncertainties in the distinction between MHC class Ia and class Ib molecules in particular because of antibody cross-reactivities both in murine [29] and human [30] systems.
Despite earlier controversies in the mouse and human systems, the weight of evidence in the literature appears now in favor of a lack of polymorphic MHC class Ia antigens on the surface of trophoblast cells lying in close contact with maternal blood cells [11, 12, 14, [31] [32] [33] [34] [35] [36] . In the mouse, some polymorphic fetal MHC class I antigens have been reported on interstitial trophoblast, mostly in the maternal decidua basalis but not on endovascular trophoblast [37] [38] [39] . In the human placenta, MHC class Ia human leu- kocyte antigen (HLA)-A and -B appear to be absent throughout pregnancy while MHC class Ib molecules HLA-G are expressed on extravillous cytotrophoblast tissue, along with low amounts of HLA-C molecules according to some reports [40] [41] [42] . HLA-G molecules have been shown to protect cells from natural killer cell-mediated lysis in vitro [43] .
Previous work from our laboratory has shown that the expression of a Tg H-2K b molecule early in development under the control of a housekeeping gene promoter leads to the loss of Tg embryos due to developmental lethality [44] . To assess directly the contribution of the negative regulation of MHC antigens in the placenta to the survival of the fetus, we have produced Tg mice expressing the mouse MHC class I molecule, H-2K b exclusively in the placenta, on a pure Fvb (H-2 q ) background. For this purpose, we have placed the H-2K b gene under the control of the mouse placental lactogen type II minimal promoter described by Shida et al. [45] . The activity of this minimal promoter is restricted, in Tg mice, to the trophoblast giant cells during the second half of gestation. Our results indicate that the forced expression of the H-2K b molecule restricted to trophoblast giant cells does not induce a rejection or developmental failure of the fetus but may contribute to the acquisition of maternal tolerance via the antigen-specific deletion of bone marrow B cells.
MATERIALS AND METHODS

Mice
Fvb (H-2 q ), C57Bl/6(H-2 b ), (Fvb ϫ C57Bl/6)F 1 (H-2 q/b ), and C57Bl/ 10.D2, lpr/lpr (B10.D2, H-2 d ) mice have been bred and kept at the J. Monod Institute's facilities, according to institutional guidelines. The 3.83 BcR anti-H-2K k,b Tg mice (on B10.D2 background) have been described previously [46] and originated from animals kindly provided by Dr. David Nemazee (Scripps Research Institute, La Jolla, CA). Animals were used between 6 and 12 wk of age.
Gene Construct
A 5.7-kilobase (kb) NruI/EcoRI genomic fragment containing the H-2K b gene [47] without its promoter sequence was cloned into the pO1mpLII plasmid containing the mouse placental lactogen II gene minimal promoter [45] (Fig. 1) . The new construct was named pmpLII-H-2K b .
Production of Tg Mice
The transgene construct was separated from bacterial vector sequences by digestion with MluI and agarose gel electrophoresis. The fragment was isolated and purified on Elutip-columns (Schleicher and Schuell, CeraLabo, Ecquevilly, France) according to the manufacturer's recommendations.
Transgenic mice were produced by classic microinjection techniques [48] . Zygotes were obtained from superovulated Fvb female mice mated with Fvb males the night before. About 500 copies of the construct were microinjected into the male pronucleus, and eggs at the 1-cell stage were reimplanted into the infundibulum of pseudopregnant (Fvb ϫ C57Bl/6)F 1 foster mothers.
Genomic Southern Blots
DNA was isolated from tail samples taken from 2-to 3-wk-old pups. Twenty micrograms of DNA from putative Tg mice founders and non-Tg Fvb mice was digested with BglII. For the determination of the transgene copy number in each strain, 1, 5, or 10 copies of the transgene insert digested by BglII were added to 20 g of Fvb genomic DNA. Fragments were separated by 0.8% agarose gel electrophoresis, transferred onto nylon membrane (Qiabrane, Qiagen, France), and hybridized with an ␣-32 P-labeled probe (Fig. 1) . The bands were detected and quantified on a phosphoimager.
Polymerase Chain Reaction (PCR) Assays
PCR assays were performed in a final volume of 25 l containing 100 ng of purified genomic DNA or 10 ng of pmpLII-H-2K b transgene DNA (as a positive control) in PCR buffer (10 mM Tris-HCl, 50 mM KCl, 1 mM MgCl 2 , 0.1% Triton X-100, 10% dimethylsulfoxide), 0.2 mM of dNTPs, 1 mM of each oligonucleotide primer, and 1 U of Taq DNA polymerase (Promega, Charbonnieres, France). The pmpLII-H-2K b -specific DNA was amplified using the following primers ( Fig. 1 ): pmpLII-specific sense primer (a), GGGGATCATCGCGAATCGCCG, located 3Ј of the transcription start site just before the ATG of exon I, and H-2K b -specific anti-sense primer (b), CCCCTCCTGCTCCATCCACCG, under the following conditions: a 2-min denaturing step at 94ЊC followed by 30 amplification cycles of 1 min at 94ЊC, 1.5 min at 60ЊC, 1 min at 72ЊC, and a final elongation step at 72ЊC for 10 min. The expected size of the amplification product was 454 base pairs (bp). PCR products were analyzed on 2% agarose gels containing ethidium bromide (0.05 g/ml). The actinspecific sense and anti-sense primers were GGTTCCGATGCCCTGAGG-CTC and ACTTGCGGTGCACGATGGAGG, respectively. The 4311 gene is a specific marker of spongiotrophoblast [49] , the primers were: sense, GCAAGAGCAGAAGGATAAAG and anti-sense, AACTTCATA-CTGCTGTCCA.
RNA Preparation and Reverse PCR
Nontransgenic and pmpLII-H-2K b -Tg Fvb placentas were removed from Fvb pregnant females on Days 9.5-16.5 postcoitum (pc). Total RNA was isolated as described previously by Chomczynski et al. [50] and treated with DNAse to prevent genomic DNA contamination. Two micrograms of placental RNA were incubated for 30 sec at 90ЊC with a specific primer (c) ATAGTGTGAGAGCCGCC localized in the second and the third exons of H-2K b RNA (Fig. 1 ). Complementary DNA was synthesized for 60 min at 42ЊC in a 10-l reaction volume containing 50 mM Tris-HCl buffer (pH 8.3), 50 mM KCl, 10 mM MgCl 2 , 0.5 mM spermidin, 10 mM dithiothreitol, 0.5 mM dNTPs, 3 U RNAsin, and 1 U of reverse transcriptase (Promega). The pmpLII-H-2K b transgene cDNA has been detected by PCR reaction as described above. The expected size of the amplified product was 267 bp. PCR products were analyzed on 2% agarose gels containing ethidium bromide (0.05 g/ml). For actin, the reverse transcription (RT) primer was identical to the PCR antisense, ACTTGCGGTGCAC-GATGGAGG; and for 4311, the RT primer was GCTGTTTCGCTCGTT-GCCTA.
Immunocytochemistry
Nontransgenic and pmpLII-H-2K b -Tg Fvb placentas were removed from Fvb pregnant females at Days 10.5-18.5 pc and bathed in 1ϫ PBS (pH 7.4). The placentas were fixed for 1 h at 4ЊC with 4% paraformaldehyde in PBS. For the detection of MHC antigens, this fixation step was omitted. Tissues were incubated sequentially in 1ϫ PBS solutions containing 5%, 10%, and 25% sucrose, at 4ЊC. Placentas were covered with Cryo-M-Bed (Bright Instruments, Huntingdon, UK) and frozen in liquid nitrogen. Five-micron placenta cryosections (Bright Instruments) were placed on superfrost-plus slides and stored at Ϫ80ЊC. Air-dried placenta cryosections were fixed for 10 min with acetone at 4ЊC. Each sample was treated at room temperature for 30 (AF6-88.5), or anti-H-2K q (KH114), or anti-H-2K k (36-7-5) monoclonal antibodies (BD-Pharmingen, Le Pont de Claix, France), rabbit immune sera specific either for the mouse placental lactogen type II provided by Pr. F. Talamantes [51] or for the H-2K b peptide encoded by exon 8 provided by Dr. B. Barber [52] , followed by peroxidase-coupled goat antirabbit antibodies (Sigma-Aldrich St Quentin Fallavier, France). Placenta sections were then washed with PBS-BSA. Biotin-coupled antibodies were revealed by a peroxidase-coupled streptavidin (Vector, Abcys, Paris, France). Peroxidase activity was detected with 3-amino-9-ethyl-carbamazole into acetate buffer (pH 5) (AEC staining kit from Sigma). After counterstaining for 20 sec with Mayer hematoxylin solution and washes, the slides were mounted with coverslips and examined under a light microscope, equipped with a Coolsnap color charge-coupled device camera (Princeton Instruments, Evry, France) connected to a G4 MacIntosh computer (Apple, Paris, France).
Flow Cytometry Analyses
The detailed procedure has been previously described [25] . Cells were isolated from the bone marrow and spleen of individual mice and they were resuspended in staining buffer (Hanks balanced salt solution with 4% heat-inactivated fetal calf serum and 0.1% NaN 3 ). Bone marrow cells were flushed from the long bones of hind legs of pregnant (Day 12.5-18.5 pc) 3.83 Tg mice, and spleen was gently teased on a metal sieve. Cell suspensions were submitted to red blood cell lysis, washed, and stained with the following antibodies: monoclonal antibody anti-B220 (RA3-6B2) coupled to biotin (Pharmingen), polyclonal goat anti-mouse IgM antibodies coupled to fluorescein isothiocyanate (Southern Biotechnology Associates, Birmingham, AL). Phycoerythrin-coupled streptavidin (Southern Biotechnology Associates) was used to reveal biotinylated antibodies. At least 10 000 B220-positive cells were gated from each sample and analyzed for other cell markers. All analyses were performed on an Elite-ESP from Beckman-Coulter (Roissy, France).
Statistical Analyses
Comparisons of mean values from each animal group were performed using ANOVA tests followed by posthoc comparisons of the means by Bonferonni-Dunn method, when appropriate. Alpha levels were set at 0.05 for each analysis. All analyses were performed using Statview 5.0.1 software (Abacus Concepts, Berkeley, CA) for the Macintosh.
RESULTS
Detection of pmpLII-H-2K b -Tg Founder Mice
Three Tg founder mice were detected out of a progeny of 21 newborn animals (14%). The genomic Southern blot ( Fig. 2A) revealed one extra band of 6 kb in each founder mouse. We determined that founder mouse 5001 has integrated seven copies of the transgene, founders 4001 and 3001 have integrated four and five copies, respectively (2.5 kb band in Fig. 2B ). Each founder mouse was able to produce a fertile Tg progeny, thus starting three Tg mouse lines nos. 30, 40, and 50.
Expression of pmpLII-H-2K
b mRNA Is Restricted to the Placenta During Embryonic Development
The expression of the pmpLII-H-2K b mRNA was first analyzed by RT-PCR using total RNA from Tg placentas harvested at various stages of pregnancy, from crosses between Tg males and non-Tg females. Figure 3 (Fvb ϫ pmpLII-K b ) and non-Tg (Fvb ϫ Fvb) F 1 placentas (Fig. 4, A and D) . Monoclonal antibodies specific for conformational epitopes of the H-2K b molecule specifically label clusters of trophoblast giant cells (Fig. 4E) but not in non-Tg placentas (Fig. 4B) . Moreover, we have used polyclonal antibodies raised against a portion of the cytoplasmic tail of the H-2K b molecule encoded in the exon 8 [52] . This reagent is not haplotype specific and can recognize unfolded H-2 molecules. Such antibodies label a wider part of the placenta, corresponding to the decidua and the giant cell layers in Tg placentas (Fig. 4F ) but only the decidua in non-Tg counterpart (Fig. 4C) . As expected, irrelevant control antibodies do not show any reactivity, while antibodies specific for the maternal MHC antigens stain the decidua only. Paternal or maternal MHC antigens are not detected in the trophoblast (data not shown).
It should be noted that this overall staining pattern for H-2K b is detectable only in Tg line 40. The trophoblast giant cells of Tg lines 30 and 50 are not stained by anticonformational antibodies but only by antibodies anti-exon 8-encoded peptide that recognize the unfolded H-2K b molecules (data not shown). Subsequent experiments were carried out on Tg mouse line 40.
Expression of the Tg H-2K b Molecule in the Placenta Does Not Interfere with Fetal Development or Survival
To determine whether the expression of the H-2K b molecule in giant cells could induce a maternal immune rejection of Tg embryos, we have first compared the litter size and health, as well as the yield of Tg pups in the progeny of histoincompatible Fvb versus histocompatible (Fvb ϫ C57BL/6)F 1 foster mothers. The pmpLII-H-2K b Tg founder male produced a comparably abundant progeny both from Fvb and (Fvb ϫ C57BL/6)F 1 females. The frequency of Tg newborns was similar between the two groups of females. Moreover, no augmentation in embryonic lethality, resorption number, and developmental defects or anomalies could be detected in histoincompatible gestations (data not shown). The same experiment was repeated with the following females crossed with Tg males: 1) multiparous Fvb females; 2) Fvb females hyperimmunized with C57BL/6 spleen cells prior to mating; 3) Fas-deficient (lpr/lpr) multiparous B10.D2 females. As shown in Table I , in every case, the litter size and the frequency of Tg newborns was not lower than control primiparous Fvb gestations that present the expected frequency of about 50%. These results demonstrate that the expression of the Tg H-2K b molecule in the giant cells of the placenta during the second half of gestation does not induce a maternal rejection of Tg fetuses, even in a hyperimmunized mother or after several gestations. The same observations can be made when it is combined with a maternal Fas deficiency, although the mutation in the Fas death receptor should protect maternal activated cells from destruction via Fas-ligand-bearing cells in the placenta.
Placental Expression of the Tg H-2K b Molecule Leads to Maternal Bone Marrow B Cell Deletion in 3.83 BcR-Tg Mothers
Previous results from our laboratory [25] , using the 3.83 anti-H-2K k,b BcR-Tg mouse model, have shown that maternal B cells specific for paternally inherited H-2K k fetal MHC antigens are deleted from the spleen, blood, and bone marrow during the second half of gestation. This deletion significantly affects from 40% to 80% of the B220
ϩ Tg B cells in these organs [25] . The main, but not only, target of the deletion is immature IgM hi , B220 low to intermediate (B220 lo to int. ) B lymphocytes, also called transitional B cells [53] [54] [55] . , the C57Bl/6, and the FvB control group, as supported by the ANOVA test performed on the three groups (groups are not comparable, P Ͻ 0.05). Post hoc comparisons (Bonferroni/ Dunn) show that the differences between the C57Bl/6, and the FvB group (P Ͻ 0.05) or between mpLII-K b Tg and FvB (P Ͻ 0.01) are significant, while the C57Bl/6 and the mpLII-K b Tg groups do not differ significantly. Spleen cells: 15.9 Ϯ 1.1 in the FvB group (n ϭ 7), 14.2 Ϯ 1 in the C57Bl/ 6 group (n ϭ 5), and 15.8 Ϯ 0.9 in the mpLII-K b Tg group (n ϭ 11). In the spleen analyses, mean values are not significantly different, according to the statistical tests performed (ANOVA and post hoc comparisons).
We have used the same BcR-Tg mouse model to determine whether the H-2K b molecules borne by Tg trophoblast giant cells could be detected by BcR-Tg maternal B cells and whether this interaction had any effect on their fate. As shown in a typical experiment presented in Figure 5A , transitional B220 lo to int , IgM ϩ bone marrow B cells in control crosses (BcR-Tg females crossed with non-Tg Fvb males) represent 46% on Day 13.5 and 22% on Day 17.5 of gestation. This percentage is down to 15% (Day 13.5) and 5% (Day 17.5), when the BcR-Tg females have been crossed with C57/Bl6 males and bear H-2K b -positive fetuses. This difference is statistically significant (P Ͻ 0.05). Interestingly, when BcR-Tg females were crossed with pmpLII-H-2K b Tg males, the percentages of transitional B cells (14% and 8%) are comparable to that of the C57Bl/6 mating (no statistically significant difference between these two groups), even though the H-2K b antigen is restricted to the giant cells of the placenta. Moreover, the amplitude of the deletions is increasing with time between Days 13.5 and 17.5 pc, comparably in both experimental crosses. Again, the differences between the pmpLII-H-2K b Tg group and the Fvb control are highly significant (P Ͻ 0.01).
In the spleen, no significant difference is observed between the three groups, even at the level of immature IgM hi B cells (see boxes in Fig. 5A ). The percentages of immature B cells in maternal bone marrow and spleen from the three different crosses, in five separate experiments, have been compiled in Figure 5B .
These results strongly suggest that the Tg H-2K b molecules borne by trophoblast giant cells during the second half of gestation are detected by the 3. 
DISCUSSION
Evolution probably selected a large number of mechanisms contributing to successful viviparity and therefore to the survival of mammalian species. The identification of these mechanisms is made difficult by the large number and pleiotropic activities of the contributing agents. The present work addressed the longstanding question of the role of the negative regulation of polymorphic MHC molecules in the mouse placenta. We have produced Tg mice for an MHC class I molecule, H-2K b , placed under the control of the minimal promoter of the mouse placental lactogen type II. We have shown that, at the mRNA level, the transgene is expressed only in the placenta, from Day 10.5 pc till the end of gestation. Several reports in the literature have indicated that giant cells, sitting close to maternal decidual cells, do not express polymorphic MHC class I or II antigens at any time during pregnancy. Our results are in complete agreement, as we have observed no specific staining on trophoblast cells with antibodies against paternal or maternal MHC antigens, while maternal MHC antigens could be easily revealed on decidual cells. One group has proposed that the lack of MHC expression on giant cells is due to the absence of ␤2-microglobulin [33, 34] . Our data indicate that giant cells can express MHC class I molecules when provided with the Tg mRNA for the MHC class I ␣ chain. Giant cells could be stained by polyclonal rabbit antibodies specific for the peptide encoded in exon 8 of H-2 molecules. This reagent binds the cytoplasmic tail of H-2 molecules, even when not properly folded. The amount of available ␤2-microglobulin and/or stabilizing peptide could be a limiting parameter for the expression of properly folded H-2K b molecules. We do not know at present whether the ␤2-microglobulin comes from the giant cells themselves, other neighboring cells, or maternal or fetal blood. Likewise, the origin of the stabilizing peptide(s) is not known, as little if any information is available on the antigen presentation capacity of giant cells.
In spite of this expression of MHC molecules on the placenta, no perturbation could be detected in fetal development or survival, even in multiparous females. Similarly, no counterselection of Tg embryos was observed after hyperimmunization of histoincompatible mothers with H-2K bbearing cells. Previous reports in the literature [15, [56] [57] [58] have shown that the placenta can be an immune-privileged site like the eye or testis, as Fas-ligand-bearing placental cells are able to trigger apoptosis of maternally activated cells expressing elevated levels of the Fas death receptor. We have analyzed the reaction of female mice that lacked a functional Fas receptor and found no difference in the average litter size or frequency of Tg pups.
Our results are in agreement with the study by Rogers et al. [59] who have produced Tg mice expressing the H-2L d molecule in giant cells of the trophoblast under the control of the same promoter as in the present work. They did not observe any adverse effect on pregnancy outcome. However, the L d -Tg mouse line has been backcrossed to Balb/c (H-2 d ) animals so that all experimental gestations involve paternal H-2L d -expressing fetuses as well as Tg H-2L d -expressing placentas. Three other reports in the literature have described different Tg mouse models where Tg MHC class I molecules have been expressed in the placenta, with conflicting results. Only one of them [60] describes a counterselection of Tg embryos, expressing the H-2D d molecule under the control of the c-fos promoter, but both in MHC-compatible and -incompatible pregnancies. The two other works report no effect of the transgene expression on pregnancy outcome [61, 62] . In our system, no H-2K b is present in Tg fetuses and the female/male combination can be made completely syngeneic (Fvb ϫ Fvb) so that the only antigenic difference comes from the placenta. Under this strictly controlled experimental setup, we show that the maintenance of maternal tolerance is not due to a lack of alloantigen recognition or ignorance, as flow cytometry analyses in the 3.83 BcR-Tg model bring the definite proof that maternal bone marrow B cells are specifically affected by the H-2K b placental antigens.
Two groups have studied the influence of Tg placental alloantigens on TcR-Tg maternal T cells, with different outcomes. Rather surprisingly, in the system described by Zhou et al. [62] , the H-2K b molecule under the control of the HLA-G promoter leads to an expanded cohort of BM3 TcR-Tg anti-H-2K b CD8
ϩ T cells in the spleen and draining lymph nodes of the mother. In contrast, Rogers et al. [59] did not see any consequence of the L d transgene expression on 2C TcR-Tg anti-L d maternal T cells in lymph nodes. We present evidence for a specific signalling to maternal bone marrow B lymphocytes. Our results show that the amount of specific bone marrow B cell deletion caused by placental antigens is comparable to what is observed in a (3.83 BcRTg female ϫ C57Bl/6 male) cross where H-2K b antigens come from F 1 fetuses. The kinetics of these phenomena appear remarkably parallel. Whether the same route and mechanisms take place in both cases remains to be determined. It should be noted that such a deletion does not occur in crosses of 3.83 BcR-Tg females with Tg males from pmpLII-K b Tg lines 30 or 50 that do not express properly folded H-2K b molecules in the placenta.
In keeping with our previous observations on (3.83 BcRTg female ϫ B10.BR [H-2 k ] male) crosses [25] , this antigen-specific deletion is superimposed with the downregulation of B lymphopoiesis due to gestational estrogens, previously reported by Medina et al. [21] . The main target of the antigen-specific deletion appears to be a transitional B220 lo to int , IgM hi bone marrow B cell. This particular population of immature B cells has been shown to be a major target for negative selection and tolerance acquisition events during normal B cell development, eliminating selfreactive lymphocytes in this particular developmental phase when they are highly sensitive to tolerance acquisition signals. The physiological role of such a deletion during pregnancy would be to deplete the pool of newly made maternal bone-marrow B cells from potentially harmful ones toward the fetus. In 3.83 Tg nonpregnant female mice, these immature B cells are abundant in bone marrow (about two thirds of B220 ϩ cells) and represent a minor subpopulation in the spleen (less than 5%, our unpublished results).
Our previous results [25] on B10.BR (H-2 k ) crosses showed that more mature peripheral splenic BcR-Tg B cells could also be a target for the H-2K k antigen-specific deletion, while our present data show that they are not significantly affected by the placental or fetal H-2K b antigens. This difference is likely to result from the much lower affinity of the 3.83 Tg BcR for H-2K b than for H-2K k antigens, leading to different signalling capacities to Tg B cells. As previously reported in the same Tg model, altering the frequency of antigen-bearing cells within the same mouse has different consequences on the B cell fate [63] . The weaker, lower-affinity interactions of the H-2K b antigens with the Tg BcR affect the most tolerance acquisition-sensitive B cell populations, i.e., the transitional B lymphocytes that are numerous in the bone marrow. The amplitude of the bone marrow deletion increases with time during the second half of gestation. Most probably, this is the result of an increase in antigen source as the number of trophoblast giant cells increases as well as the activity of the mpLII promoter. The migration of some giant cell clusters to the labyrinthine zone of the trophoblast around Day 15 pc could also facilitate the recognition of the Tg MHC antigens by maternal cells in blood lacunae that are abundant in this area of the placenta.
In conclusion, this is the first report of the consequences, on maternal B lymphocytes, of Tg MHC antigens expressed in placental giant cells only. Although the pregnancy outcome is not compromised, our data provide evidence of signalling to maternal-specific B cell precursors in the bone marrow, thus possibly contributing to fetal development in the absence of maternal aggression.
